(Q46845991)

25 December 2017

title

Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (English)

1 reference

25 December 2017

main subject

Stevens–Johnson syndrome

1 reference

1

1 reference

25 December 2017

author name string

Julian B Arbuckle

2

1 reference

25 December 2017

Clive E Bowman

3

1 reference

25 December 2017

Margaret Brunner

4

1 reference

25 December 2017

Daniel K Burns

5

1 reference

25 December 2017

Olivier Delrieu

6

1 reference

25 December 2017

Lynn P Dix

7

1 reference

25 December 2017

John A Twomey

8

1 reference

25 December 2017

Robert S Stern

9

1 reference

25 December 2017

publication date

1 December 2007

1 reference

25 December 2017

published in

Pharmacogenomics

1 reference

25 December 2017

volume

8

1 reference

25 December 2017

page(s)

1661-1691

1 reference

25 December 2017

issue

12

1 reference

25 December 2017

Severe adverse cutaneous reactions to drugs

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Cutaneous disease and drug reactions in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Genetic susceptibility to adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

HLA antigens in Stevens-Johnson syndrome with ocular involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Immunogenetics of drug-induced bullous diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Cytochrome P450 enzyme polymorphisms and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

HLA-B locus in Caucasian patients with carbamazepine hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Visualizing gene determinants of disease in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Genetic factors in the predisposition to drug-induced hypersensitivity reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Clinical heterogeneity of drug hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Gene map of the extended human MHC.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Role of Drug Disposition in Drug Hypersensitivity: A Chemical, Molecular, and Clinical Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

Reply to 'Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10'

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1661

10.2217/14622416.8.12.1661

21 January 2018

Identifiers

DOI

1 reference

25 December 2017

PubMed ID

18085998

1 reference

25 December 2017